Trial of Potential Universal Flu Vaccine Opens at NIH Clinical Center

National Institute of Allergy and Infectious Diseases sent this bulletin at 06/28/2022 12:17 PM EDT

Tuesday, June 28, 2022

Trial of Potential Universal Flu Vaccine Opens at NIH Clinical Center

volunteer in trial of BPL-1357 universal flu vaccine candidate receives intramuscular injection

A Phase 1 clinical trial of a novel influenza vaccine has begun inoculating healthy adult volunteers at the NIH Clinical Center in Bethesda, Maryland. The placebo-controlled trial will test the safety and ability to prompt immune responses of a candidate vaccine, BPL-1357, that was developed by NIAID researchers. The single-site trial, which can enroll up to 100 people aged 18 to 55 years old, is led by NIAID investigator Matthew J. Memoli, M.D.

National Institute of Allergy and Infectious Diseases | National Institutes of Health

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help.

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).